Your browser doesn't support javascript.
loading
Disease recurrence in patients with Crohn's disease after biologic therapy or surgery: a meta-analysis.
Kneißl, Sarah; Stallhofer, Johannes; Schlattmann, Peter; Stallmach, Andreas.
Afiliação
  • Kneißl S; Department of Internal Medicine IV (Gastroenterology, Hepatology, and Infectious Diseases), Jena University Hospital, Am Klinikum 1, 07747, Jena, Germany.
  • Stallhofer J; Department of Internal Medicine IV (Gastroenterology, Hepatology, and Infectious Diseases), Jena University Hospital, Am Klinikum 1, 07747, Jena, Germany.
  • Schlattmann P; Institute for Medical Statistics, Informatics and Data Science, University Hospital Jena, Bachstr. 18, 07743, Jena, Germany.
  • Stallmach A; Department of Internal Medicine IV (Gastroenterology, Hepatology, and Infectious Diseases), Jena University Hospital, Am Klinikum 1, 07747, Jena, Germany. andreas.stallmach@med.uni-jena.de.
Int J Colorectal Dis ; 37(10): 2185-2195, 2022 Oct.
Article em En | MEDLINE | ID: mdl-36149447
ABSTRACT

BACKGROUND:

Relapse is a problem in patients with Crohn's disease (CD) after medical therapy (including biologics) and after surgery to treat acute inflammation. It is unclear whether the recurrence rate over time is higher after surgical therapy than after continuous drug treatment.

AIM:

We sought to compare clinical relapse rates and the need for re-interventions (resection or therapeutic endoscopic intervention) in patients with CD.

METHODS:

A meta-analysis was performed according to PRISMA guidelines.

RESULTS:

The need for one of the three re-interventions (surgery, biologics or both) increased over time. The recurrence rates in patients after ileocecal resection were lower than the rates under biologic therapy. The odds ratio for clinical recurrence under biologics versus after surgical treatment was 2.50 (95% confidence interval [CI] 1.53-4.08, p-value < 0.001). The odds ratio for surgical recurrence under biologics versus after surgery was 3.60 (95% CI 1.06-12.3, p-value 0.041).

CONCLUSION:

These findings support surgical resection as a treatment option in patients with CD with limited disease.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Cirurgia_oncologica Base de dados: MEDLINE Assunto principal: Produtos Biológicos / Doença de Crohn Tipo de estudo: Guideline / Systematic_reviews Limite: Humans Idioma: En Revista: Int J Colorectal Dis Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Cirurgia_oncologica Base de dados: MEDLINE Assunto principal: Produtos Biológicos / Doença de Crohn Tipo de estudo: Guideline / Systematic_reviews Limite: Humans Idioma: En Revista: Int J Colorectal Dis Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Alemanha